-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Boston Scientific, Lowers Price Target to $65

Benzinga·09/21/2026 13:48:56
Listen to the news
Oppenheimer analyst Suraj Kalia maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $85 to $65.